Incyte CorporationNASDAQ: INCY

Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Jul 11, 2023 · Issued by Incyte Corporation via Business Wire

Watch Incyte explain itIncyte Corporation (INCY) Q2 2026 Earnings Call · Replay · Jul 28

Phase 3 TruE-AD3 Study met its primary endpoint

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura®) in children (age ≥2 to